Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication

Brent J. Passer, Tooba Cheema, Bingsen Zhou, Hiroaki Wakimoto, Cecile Zaupa, Mani Razmjoo, Jason Sarte, Shulin Wu, Chin Lee Wu, James W. Noah, Qianjun Li, John K. Buolamwini, Yun Yen, Samuel D. Rabkin, Robert L. Martuza

研究成果: 雜誌貢獻文章同行評審

22 引文 斯高帕斯(Scopus)

摘要

Oncolytic herpes simplex virus-1 (oHSV) vectors selectively replicate in tumor cells, where they kill through oncolysis while sparing normal cells. One of the drawbacks of oHSV vectors is their limited replication and spread to neighboring cancer cells. Here, we report the outcome of a high-throughput chemical library screen to identify small-molecule compounds that augment the replication of oHSV G47Δ. Of the 2,640-screened bioactives, 6 compounds were identified and subsequently validated for enhanced G47Δ replication. Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative nucleoside transporter-1 (ENT1). Replicative amplification promoted by dipyridamole and dilazep were dependent on HSV mutations in ICP6, the large subunit of ribonucleotide reductase. Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity.

原文英語
頁(從 - 到)3890-3895
頁數6
期刊Cancer Research
70
發行號10
DOIs
出版狀態已發佈 - 五月 15 2010

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication」主題。共同形成了獨特的指紋。

引用此